Drug Topics May 2021

Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma

May 11, 2021

Melphalan flufenamide (Pepaxto; Oncopeptides AB) in combination with dexamethasone was granted accelerated approval on February 26, 2021, by the FDA for adult patients with relapsed or refractory multiple myeloma.